This FOA invites applications that address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimer's disease and related dementias (ADRD) and their families. Research that either employs (a) secondary analysis of existing data from longitudinal cohort studies or from administrative records or (b) primary data collection for Stage I behavioral intervention development is particularly encouraged.
This Funding Opportunity Announcement (FOA) invites research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
This RFA [RFA-MH-18-610] uses the R01 grant mechanism while the companion RFA [RFA-MH-18-611] uses the R21 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 [RFA-MH-18-611] mechanism, while applicants with preliminary data and a discrete, specified, circumscribed project can apply using the R01 [RFA-MH-18-610] mechanism.
This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training.
This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users are allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.
This funding opportunity announcement (FOA) issued by the National Institute of General Medical Sciences encourages innovative, interactive Program Project grant applications from institutions/organizations that propose to conduct research which aims to solve a significant biological problem, important for the mission of NIGMS, through a collaborative approach involving outstanding scientists. The Program Project grant is designed to support research in which the funding of several interdependent projects as a group offers significant scientific advantages over support of these same projects as individual regular research grants.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.
The McGovern Institute for Brain Research at the Massachusetts Institute of Technology was established in 2000 by Patrick J. McGovern and Lore Harp McGovern, with the goal of improving human welfare, communication, and understanding through their support for neuroscience research.
The institute has announced a call for nominations for its twelfth annual Edward M. Scolnick Prize in Neuroscience.
Now in its fifteenth year, the Scolnick Prize is designed to recognize outstanding advances in the field of neuroscience. The prize, which is endowed through a gift from Merck to the McGovern Institute, consists of a $150,000 award, plus an inscribed gift. In addition, the recipient will present a public lecture at the McGovern Institute in spring 2018. A gala dinner for the recipient and invited guests follows the prize lecture.
Candidates for the award must be nominated by individuals affiliated with universities, hospitals, medicals schools, or research institutes, with a background in neuroscience. Self-nomination is not permitted.
The David Wechsler Early Career Grant for Innovative Work in Cognition supports early career psychologists pursuing innovative work in neuropsychology, intelligence and/or the assessment aspects of cognition. Those who work on positive applied neuropsychology are encouraged to apply. The grant is for up to $25,000.Applicants must:
Be psychologists with an EdD, PsyD or PhD from an accredited university.Be no more than 10 years post doctoral.Have demonstrated competence and capacity to execute the proposed work.
The purpose of this research is to identify, implement, and evaluate the use of effective strategies and tools for provider and patient use to taper and/or discontinue opioids, benzodiazepines, and other medications in which risk outweighs benefits to prevent falls, overdose, and other injuries among community dwelling older adults.
The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness.
December 15, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
This Funding Opportunity Announcement (FOA) encourages applications to develop valid markers to assess the activity of fundamental aging mechanisms in humans that may influence the risk and progression of multiple aging conditions. Projects are encouraged that focus on selected mechanism(s) that may regulate aging changes, assess multiple possible markers for these mechanisms, test methods to improve their measurement properties, characterize their variability among individuals of differing ages and within the same age cohort, and assess their relationships in humans to in vivo functions influenced by the mechanism(s) under study. It is strongly encouraged that each project includes an interdisciplinary research team with expertise, as needed, in the biology of their selected mechanism(s), biomedical aging research, clinical pathology including laboratory assays, imaging methods, human cohort studies, tissue banking, biorepository resources, and statistics. Though the principal focus of the initiative is on development of markers in humans, studies in laboratory animals may also be conducted when necessary for the development of human markers, and potential development of parallel laboratory animal markers of a given mechanism.
The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.
The purpose of this FOA is to promote the integration of experimental, analytic, and theoretical capabilities for large-scale analysis of neural systems and circuits. This FOA seeks applications for exploratory research studies that use new and emerging methods for large scale recording and manipulation of neural circuits across multiple brain regions. Applications should propose to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Studies should incorporate rich information on cell-types, on circuit functionality and connectivity, and should be performed in conjunction with sophisticated analysis of complex, ethologically relevant behaviors. Applications should propose teams of investigators that seek to cross boundaries of interdisciplinary collaboration by bridging fields and linking theory and data analysis to experimental design. Exploratory studies supported by this FOA are intended to develop experimental capabilities and quantitative, theoretical frameworks in preparation for a future competition for larger-scale, multi-component, Team-Research Circuit Programs (U19) awards.
The purpose of this Funding Opportunity Announcement (FOA) is to elucidate the etiology and pathogenesis of the neurocognitive complications associated with type 2 diabetes (T2D) with the ultimate goal of informing future strategies to mitigate the risk of these complications. Applications should propose expansions of ongoing human studies of well characterized T2D cohorts or cohorts comparing T2D with non-diabetic populations. Such expansions might include the addition of comprehensive neurocognitive measures (e.g., cognitive testing, neuroimaging, and biomarkers), clinical measures (e.g., insulin resistance, HbA1c), and/or collection of data on other risk factors (e.g., diet, obesity, micro- and macro-vascular disease, inflammation). It must be clearly explained how the collection of additional data will contribute to elucidation of the basis of neurocognitive sequelae of T2D.
The American Psychological Foundation provides financial support for innovative research and programs that enhance the power of psychology to elevate the human condition and advance human potential, both today and for generations to come.
As part of this mission, APF is accepting applications for its APF Trauma Psychology Grant. Through the annual program, a single grant of up to $3,000 will be awarded in support innovative work aimed at alleviating trauma.
To be eligible, applicants must be an early-career psychologist (no more than ten years postdoctoral); be affiliated with a nonprofit charitable, educational, or scientific institution, or governmental entity operating exclusively for charitable and educational purposes; have a demonstrated knowledge of trauma and trauma research; have demonstrated competence and capacity to execute the proposed work; and, if human participants are involved, have IRB approval from his/her host institution before funding can be awarded.
The Epilepsy Foundation has announced its seventh annual epilepsy "Shark Tank" competition for the most innovative ideas in epilepsy and seizure treatment and care.
Some examples of novel ideas include a system to detect seizures with the capacity to provide early warning to the patient or family; a treatment that stops a seizure from progressing; a system that helps patients manage their daily treatment; a device that prevents physical injury that patients may experience when in seizure; or an entirely new product concept with the promise to dramatically improve the lives of people with epilepsy.
Selected finalists will receive international recognition and compete for grants totaling $150,000 to support the development and commercialization of important new products, technologies, or therapeutic concepts.
As many as six finalists will be selected to present at the 2018 Epilepsy Pipeline Conference (San Francisco, February 22-23, 2018). Each presenter will have five minutes to present the concept, followed by five minutes of questioning. The Shark Tank event will feature live voting among audience members and a panel of judges (Sharks) representative of industry, advocacy, investors, and the research and medical communities. The winning project, or projects, deemed to be the most innovative will be announced at the conclusion of the competition.
To be eligible, applicants must demonstrate an ability to move the proposed plan to completion, showing how the prize can accelerate any step along the path to market. Inventors who submitted ideas for previous Shark Tank competitions are encouraged to re-submit their ideas if substantial progress has been made.
Founded in 1972, the Tourette Association of America (formerly known as the Tourette Syndrome Association) has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders.
To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies on all aspects of Tourette syndrome.
To be eligible, investigators are required to have an advanced degree such as a Ph.D., M.D. or equivalent or be allied professionals with advanced degrees such as R.N.s, Drs. of O.T., social workers, and related fields. Investigators from nonprofit and for-profit organizations can apply.
The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.
Group items tagged 
